Peak District Challenge
Walk, jog or run 25, 50 or 100km from the Bakewell Base Camp and take in Derbyshire’s finest scenery.
Search
Search results
ProQR announces suspension of LCA10 and USH2A clinical trials
Biotechnology company ProQR has announced that its clinical trials of sepofarsen for Leber congenital amaurosis type 10 and ultevursen for USH2A-mediated retinitis pigmentosa will be wound down with immediate effect.
Retina UK-funded discovery leads to $2.5 award for further research
A discovery made as part of research funded by Retina UK has led to a prestigious award of $2.5 million, enabling scientists to undertake more in-depth investigations and work towards a treatment for a particular type of retinitis pigmentosa.
Genetic testing: an essential topic for discussion with the IRD community
As Luxturna reaches the clinic and other gene-specific therapies for inherited retinal disease get closer to the end of the development pipeline, it is becoming ever more important that affected families can access a genetic diagnosis, potentially opening up choices around treatment and clinical trial participation.
Webinar: Ask the expert with Dr Roly Megaw
Joining us for an "Ask the Expert" session is Dr Roly Megaw.
Meet our supporters: Faye Maguire
Faye was part of #TeamRetinaUK in 2019. This is what she had to say in the run up to the race:
Meet our supporters: Ian Shorthose
Whether you're an expert runner, or a rebel *with* a cause, there's no better experience than the London Marathon!
Meet our supporters: William Taylor
Fundraising for Retina UK means a lot to me - both my dad and my nephew have been affected by inherited sight-loss, and I've seen first-hand the incredible work this charity does.
Podcast: Introducing our new chair
A new Retina UK podcast that introduces our new chair of trustees, Kathy Evans.
Potential drug targets identified for RP
A recently published study has described numerous disease mechanisms that appear to be common across different types of inherited sight loss, suggesting that there is significant potential for drug treatments that could work regardless of the underlying causative gene.